Cytek Biosciences (NASDAQ:CTKB) and HCW Biologics (NASDAQ:HCWB) Head-To-Head Analysis

HCW Biologics (NASDAQ:HCWB) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 42.7% of HCW Biologics shares are owned by company insiders. Comparatively, 10.3% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

HCW Biologics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares HCW Biologics and Cytek Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-2,849.17%	N/A	-43.48%
Cytek Biosciences	-33.02%	-7.70%	-5.89%

Earnings & Valuation

This table compares HCW Biologics and Cytek Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$422,026.00	7.70	-$30.02 million	($12.06)	-0.08
Cytek Biosciences	$201.49 million	2.75	-$66.54 million	($0.51)	-8.51

HCW Biologics has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for HCW Biologics and Cytek Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1	0	1	0	2.00
Cytek Biosciences	2	2	2	0	2.00

HCW Biologics currently has a consensus price target of $35.00, suggesting a potential upside of 3,686.24%. Cytek Biosciences has a consensus price target of $5.38, suggesting a potential upside of 23.85%. Given HCW Biologics’ higher possible upside, analysts clearly believe HCW Biologics is more favorable than Cytek Biosciences.

Summary

Cytek Biosciences beats HCW Biologics on 7 of the 13 factors compared between the two stocks.

About HCW Biologics

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

About Cytek Biosciences

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.